Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York

Hiba Narvel, Sindhu Vikash, Charan Thej Reddy Vegivinti, Abdul-Hamid Bazarbachi, M Bakri Hammami, Ansh Krishnachandra Mehta, Daniel K. Reef, Adnan Narvel, Riya Patel, Aditi Shastri, Noah Kornblum, Ioannis Mantzaris, Marina Konopleva, Dennis Cooper, Nishi Shah, Mendel Goldfinger, Ira Braunschweig, Amit Verma, R. Alejandro Sica

Blood (2022) 140 (Supplement 1): 13204–13205.

https://doi.org/10.1182/blood-2022-165704

Published: 2022

Journal Articles

Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma

Nina Samuel, Lauren Laufer, Rodrigo Tanaguchi, Joel Rosiene, Carlo Palesi, Richard Elkind, Ioannis Mantzaris, Aditi Shastri, Noah Kornblum, R. Alejandro Sica, Urvi A Shah, Dennis Cooper, Amit Verma, Nishi Shah

Blood (2022) 140 (Supplement 1): 7936–7938.

https://doi.org/10.1182/blood-2022-169443

Published: 2022

Journal Articles

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Blood (2022) 140 (Supplement 1): 11653–11655.

https://doi.org/10.1182/blood-2022-158112

Published: 2022

Journal Articles

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Blood (2022) 140 (Supplement 1): 10949–10950.

https://doi.org/10.1182/blood-2022-164841

Published: 2022

Journal Articles

Pre-Conditioning Easix Is Associated with Survival after Autologous Hematopoietic Stem Cell Transplant in Mature T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 12928–12929.

https://doi.org/10.1182/blood-2022-170810

Published: 2022

Journal Articles

A Single Center Analysis of Hematopoietic Recovery in Patients Undergoing Allogeneic BMT with Suboptimal CD34+ Doses

John X Wei, Nina Samuel, Richard Elkind, Carlo Palesi, Aditi Shastri, R. Alejandro Sica, Ioannis Mantzaris, Noah Kornblum, Kira Gritsman, Amit Verma, Mendel Goldfinger, Dennis Cooper, Nishi Shah

Blood (2022) 140 (Supplement 1): 12890–12891.

https://doi.org/10.1182/blood-2022-166689

Published: 2022

Journal Articles

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Blood (2022) 140 (Supplement 1): 13225–13227.

https://doi.org/10.1182/blood-2022-170633

Published: 2022

Journal Articles

Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis

John X Wei, Alex Sisto, Aditi Shastri, R. Alejandro Sica, Ioannis Mantzaris, Noah Kornblum, Urvi A Shah, Murali Janakiram, Kira Gritsman, Amit Verma, Mendel Goldfinger, Dennis Cooper, Nishi Shah

Blood (2022) 140 (Supplement 1): 11014–11015.

https://doi.org/10.1182/blood-2022-168978

Published: 2022

Journal Articles

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Blood (2022) 140 (Supplement 1): 3360–3361.

https://doi.org/10.1182/blood-2022-167849

Published: 2022

Journal Articles

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Blood (2022) 140 (Supplement 1): 11595–11597.

https://doi.org/10.1182/blood-2022-159826

Published: 2022

Journal Articles

Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Blood (2022) 140 (Supplement 1): 662–664.

https://doi.org/10.1182/blood-2022-170332

Published: 2022

Journal Articles

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, Jason Brayer, James E Hoffman, William I. Bensinger, Ka Lung Wu, Linzhi Xu, Dhruti Chokshi, Anita Boyapati, Manish Sharma, Karen Rodriguez Lorenc, Glenn S Kroog, Madhav V Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath

Blood (2021) 138 (Supplement 1): 160.

https://doi.org/10.1182/blood-2021-144921

Published: 2021

Journal Articles

Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population

Brandi Handel, MSN, RN, Nicole McEntee, BSN, RN, OCN, BMTCN, Anne Tyno, RN, MSN, APN-C, Patricia Andrews, BSN, RN, OCN, Patricia Lafaro, BS, RN, CIC, Vimal Patel, MD, Dale G Schaar, MD PhD, Roger Strair, MD PhD, Dennis Cooper, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142972

Published: 2020

Journal Articles

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139192

Published: 2020

Journal Articles

A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

Taxiarchis Kourelis, MD, Sikander Ailawadhi, Dan T. Vogl, MD, Dennis Cooper, MD, Tyler D Ames, PhD, Christina Y Yim, PhD, Matthew R Price, Jose J Jimeno, MD PhD, P. Leif Bergsagel, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134916

Published: 2020

Journal Articles

Narcotic Use in Multiple Myeloma Patients at the Time of ASCT and One-Year Follow up

Matthew Danish, MD MS, Tabitha Copeland, MD, Joseph Ho, MD, Mansi Shah, MD BA, Dennis Cooper, MD

Blood (2019) 134 (Supplement_1): 4726.

https://doi.org/10.1182/blood-2019-131551

Published: 2019

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Kartik Sehgal, Rituparna Das, Lin Zhang, Rakesh Verma, Yanhong Deng, Mehmet Kocoglu, Juan Vasquez, Srinivas Koduru, Yan Ren, Maria Wang, Suzana Couto, Mike Breider, Donna Hansel, Stuart Seropian, Dennis Cooper, Anjan Thakurta, Xiaopan Yao, Kavita M. Dhodapkar, Madhav V. Dhodapkar

Blood (2015) 125 (26): 4042–4051.

https://doi.org/10.1182/blood-2014-11-611426

Published: 2015

Includes: Supplemental data

Journal Articles

Caught in transformation

Mina L. Xu, Dennis Cooper

Blood (2014) 124 (17): 2749.

https://doi.org/10.1182/blood-2014-08-593913

Published: 2014

NARROW

Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York

Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Pre-Conditioning Easix Is Associated with Survival after Autologous Hematopoietic Stem Cell Transplant in Mature T-Cell Lymphomas

A Single Center Analysis of Hematopoietic Recovery in Patients Undergoing Allogeneic BMT with Suboptimal CD34+ Doses

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

Narcotic Use in Multiple Myeloma Patients at the Time of ASCT and One-Year Follow up

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Caught in transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only